{"entity":{"id":"nct04370587","kind":"trial","name":"A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Adva","aka":[],"tldr":"A phase 1/2 trial of T3011, Pembrolizumab in melanoma, run by ImmVira Pharma Co. Ltd, now recruiting.","summary":"A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04370587 by ImmVira Pharma Co. Ltd, with 30 participants planned, started 2020-09-17 and due to reach its primary completion in 2026-09-22. Interventions recorded: T3011, T3011 + pembrolizumab. Conditions listed: Solid Tumor, Melanoma, HNSCC, Sarcoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04370587","url":"https://clinicaltrials.gov/study/NCT04370587"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["t3011","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04370587","phase":"1/2","setting":"A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors","sponsor":"ImmVira Pharma Co. Ltd","enrolled":30,"outcomes":[]},"route":"/trials/nct04370587/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"t3011","kind":"drug","name":"T3011","route":"/drugs/t3011/"}],"company":[{"id":"immvira-pharma","kind":"company","name":"ImmVira Pharma","route":"/companies/immvira-pharma/"}]}}